Salute e Benessere

Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to…

More than 1 million curable sexually transmitted infections (STIs) are acquired every day worldwide in people 15–49 years old, most of which are asymptomatic. 1 FDA CLIA-waived tests broaden access to accurate, easy-to-use diagnostics for all patients in decentralized settings like urgent care centers, retail clinics, and community health venues.The tests use highly sensitive, gold-standard PCR technology, providing results in 20 minutes to allow healthcare providers to confidently...
Nasdaq GlobeNewswire
22/01/2025

Oculis Publishes Notification of Major Changes in Voting Rights

Attachment Notification of Major Changes in Voting Rights - Íslandsbanki (21 Jan 2025)
Nasdaq GlobeNewswire
21/01/2025

Nutraceuticals Market Set for 6.4% CAGR Growth to $571.3 Billion

The report forecasts the nutraceuticals market from 2024 to 2029, covering major companies and market segments such as functional beverages, foods, and supplements. Applications include wellness, weight management, heart, and digestive health. The report also analyzes distribution channels such as e-commerce, supermarkets, and pharmacies, as well as regional markets of North America, Europe, Asia-Pacific, and Rest of the World. The report forecasts the nutraceuticals market from 2024 to 2029,...
PR Newswire
21/01/2025

Pharming Group to convene Extraordinary General Meeting of Shareholders

Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces it will hold an Extraordinary General Meeting of Shareholders (EGM) on March 4, 2025, at 14:00 CET. The Notice to Convene, Explanatory Notes, Voting information, meeting documents and Form of Proxy can be found on the Company's website under Investors/Shareholder Meetings.The EGM is convened for the appointment of Mr. Fabrice Chouraqui as Executive...
Nasdaq GlobeNewswire
21/01/2025

Osteotec announces exclusive partnership with Highridge Medical to distribute…

Highridge Medical, headquartered in Westminster, Colorado, is the world's largest privately held spine company and a global leader in implantable spine solutions designed to address diverse surgical challenges. Its comprehensive product range of implants, fixation systems and biologics are supported by extensive clinical evidence and training programmes to equip surgeons with the tools and expertise needed for success. In partnering with Highridge Medical, Osteotec underscores its commitment to…
PR Newswire
21/01/2025

Wound Debridement Market Expected to Reach USD 1.162 Billion by 2031, Driven by…

Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=230918 Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=230918 202 – Pages 126 – Tables 37 – Figures Scope Of The Report Wound Debridement Market Overview 1. Market Introduction The Wound Debridement Market encompasses a range of products and procedures designed to remove dead, damaged, or infected tissue to promote faster and healthier wound...
PR Newswire
21/01/2025

Healthcare Analytics Industry to Hit USD 133.1 billion by 2029 with 24.3% CAGR |…

Browse in-depth TOC on "Healthcare Analytics Industry Outlook" Browse in-depth TOC on "Healthcare Analytics Industry Outlook" 10 - Tables 14 - Figures 70 - Pages The Global Healthcare Analytics Outlook for 2025 provides a comprehensive overview of the critical trends that shaped the sector in 2024. It offers a comparative analysis of growth rates and valuations across key segments in healthcare analytics for 2024, highlights significant trends to monitor in 2024, and…
PR Newswire
21/01/2025

Tissue Engineering Market Is Projected To Reach $7.41 Billion by 2031, At A CAGR…

Download FREE PDF Brochure Of Tissue Engineering Market - https://www.meticulousresearch.com/download-sample-report/cp_id=6089 Download FREE PDF Brochure Of Tissue Engineering Market - https://www.meticulousresearch.com/download-sample-report/cp_id=6089 Tissue engineering is the process of repairing damaged tissues using specialized cells, materials, and bioactive molecules. It involves the development of biological substitutes to restore, maintain, and enhance tissue function...
PR Newswire
21/01/2025

Precision Diagnostics & Medicine Market worth $246.66 billion by 2029 with 11.1%…

Browse in-depth TOC on "Precision Medicine Market" Browse in-depth TOC on "Precision Medicine Market" 416 - Tables 92 - Figures 445 - Pages Based on product, the precision medicine market is divided into inhibitor drugs, monoclonal antibodies, cell and gene therapy, antiviral and anti-retroviral drugs, and other therapeutic products. The large share of the monoclonal antibodies' products segment can be attributed to the fact that a large number of the approved precision...
PR Newswire
21/01/2025

Geriatric Care Services Market is expected to generate a revenue of USD 2.03…

The global geriatric population is growing rapidly, according to a World Health Organization report published in September 2024, the global population aged 60 and up is expected to double from 1 billion in 2020 to 2.1 billion in 2050. This demographic shift is fueling demand for tailored care services, creating lucrative opportunities across the healthcare, insurance, and caregiving sectors. The global geriatric population is growing rapidly, according to a World Health Organization report...
PR Newswire
21/01/2025

Glooko Secures Reimbursement for Remote Monitoring of Gestational Diabetes in…

GDM has a significant impact on maternal and fetal health in France: GDM has a significant impact on maternal and fetal health inFrance : The HAS approval is based on the recognition that Glooko XT provides a valuable complementary monitoring option for conventional medical follow-up of GDM. The specific indications for reimbursement include: Expanding reimbursement for GDM ensures equitable access to this vital technology, supporting healthier pregnancies and improved outcomes for...
PR Newswire
21/01/2025

Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference call on 4…

Tuesday, 4 February 2025 at 10.00 - 11.00am CETIn connection with the publication of Coloplast's interim financial results for Q1 2024/25, to be released same day around 07.30am CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast's website approximately 1 hour before the conference call. The webcast of the conference call will be available during and after the...
Nasdaq GlobeNewswire
21/01/2025

Datar Cancer Genetics Introduces Revolutionary Tumor-Agnostic + Informed Blood…

In patients who undergo initial anticancer treatments, a small number of tumor cells can survive and persist in the body. This low 'disease burden' is capable of leading to a relapse, which can remain undetectable by traditional genomic and imaging methods. Timely detection of this 'minimal residual disease' is now considered critical towards mitigating risks of recurrence. In patients who undergo initial anticancer treatments, a small number of tumor cells can survive and persist in the body...
PR Newswire
21/01/2025

Invitation: Sobi's Q4 and FY 2024 report

The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call. The presentation can be followed livehere or afterwards on sobi.com. The slides will be made available onsobi.com before the conference call. To participate in the conference call, please use the following dial-in details: Sweden : +46 8 5051 0031United Kingdom : +44 207 107 06 13United States : +1 631 570 56 13 For other countries,...
PR Newswire
21/01/2025

The Disposable Syringes Market Size is Estimated at $7.2 Billion in 2024 and is…

"The growing awareness among healthcare professionals about safety protocols related to injections has led to a higher preference for disposable syringes over reusable ones, driving the global demand for disposable syringes. Moreover, disposable syringe manufacturers are expanding their production of dual-chamber syringes, which are capable of delivering two drugs simultaneously. This shift toward specialized syringe manufacturing is gaining popularity across the market, subsequently…
PR Newswire
21/01/2025

NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study…

PARIS and CAMBRIDGE, Mass., Jan.21, 2025(GLOBE NEWSWIRE) --NANOBIOTIX(Euronext: NANO –– NASDAQ: NBTX – the '' Company ''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that the first patient has been dosed in the CONVERGE study, a Phase 2 randomized controlled clinical trial evaluating potential first-in-class radioenhancer JNJ-1900...
Nasdaq GlobeNewswire
21/01/2025

Half-year report

DXS INTERNATIONAL PLC(AQSE: DXSP)HALF YEAR RESULTS DXS International plc ("DXS" or the "Company"), the digital clinical decision support company, is pleased to provide shareholders with its unaudited interim results for the half year ending 31 October 2024. Financial highlights:Revenue increased by 2.2% to £1,730,829 (2023 - £1,693,910).Core recurring revenue model remains resilient.Profit after tax of £1,131 compared to a loss of (£121,567) in 2023, an improvement of...
Nasdaq GlobeNewswire
21/01/2025

Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights

Press ReleaseNicox Provides Business Update and Fourth Quarter 2024 Financial Highlights Last patient recruited in the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical trial with topline results expected in Q3 2025 Fourth quarter 2024 Nicox Group revenue of €13.7 million Cash of €10.7 million as of December 31, 2024, following a €5.2 million debt repayment, which the Company estimates will finance it into the third quarter of 2025 January 21, 2025 – release...
Nasdaq GlobeNewswire
21/01/2025

Press Release: Opella reaches study milestone for Cialis

Opella reaches study milestone for CialisParis, January 21, 2025. Opella, Sanofi's Consumer Healthcare business, announced that the US Food and Drug Administration (FDA) has lifted a clinical hold on its planned actual use trial (AUT) to support the switch of Cialis (tadalafil) from a prescription to an over-the-counter medicine. This decision allows for the initiation of the AUT and makes Cialis the first PDE-5 inhibitor to achieve this milestone.AUTs evaluate the use of the...
Nasdaq GlobeNewswire
21/01/2025

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive…

Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has nominated Fabrice Chouraqui to become Pharming's new Executive Director and Chief Executive Officer, succeeding Sijmen de Vries.Pharming will nominate Mr. Chouraqui for the appointment as Executive Director and Chief Executive Officer for a term of four years at an upcoming Extraordinary General Meeting of...
Nasdaq GlobeNewswire
21/01/2025

IBA and Wallonie Entreprendre International secure 30% stake in mi2-factory to…

Louvain-La-Neuve, Belgium, 21 January 2025- IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, and Wallonie Entreprendre International (WE International), the international branch of the Walloon public investment company, today announce a joint strategic investment of EUR 5 million each in mi2-factory, a start-up and spin-off from the University of Applied Sciences Jena, Germany. This investment secures a 15% stake for IBA and a 15% stake for...
Nasdaq GlobeNewswire
21/01/2025

Oculis Publishes Notification of Major Changes in Voting Rights

Attachment Notification of Major Changes in Voting Rights - Íslandsbanki
Nasdaq GlobeNewswire
20/01/2025

Publication relating to transparency notifications

REGULATED INFORMATIONPublication relating to transparency notificationsMont-Saint-Guibert(Belgium), January 20, 2025 , 10:30 pm CET / 4:30 pm ET –In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.BlackRock, Inc.On January 16, 2025, Nyxoah received a transparency notification from...
Nasdaq GlobeNewswire
20/01/2025

MicroAire Completes Acquisition of NEOSYAD

Strengthening MicroAire's Adipose Tissue Leadership Strengthening MicroAire's Adipose Tissue Leadership MicroAire's PAL ®handpiece is the #1 power-assisted liposuction device inthe United Statesand a global leader among plastic surgeons. The acquisition of NEOSYAD marks a significant step forward in MicroAire's vision to strengthen its leadership in the global adipose tissue market.Jerome Barrillon, President of MicroAire, shared his enthusiasm for the partnership:"We are...
PR Newswire
20/01/2025
Altri  Comunicati